At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Treatment Study for Patients with Newly Diagnosed Stage III Non-Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of a combined course of chemotherapy and radiation (chemoradiation) followed by immunotherapy (durvalumab) for poor risk or elderly patients with locally advanced non-small cell lung cancer (NSCLC). Combined chemoradiation followed by durvalumab is standard of care/FDA approved for patients with an excellent performance status (i.e. very “fit” patients); some combination or sequencing of chemotherapy with radiation (NOT followed by immunotherapy) is standard for poor risk/elderly patients. However, the chemoradiation followed by durvalumab approach is novel/investigational in poor risk or elderly patients. The term “investigational” means that it has not been approved by the U.S. Food and Drug Administration (FDA) and must be tested to see if it is a safe and effective treatment method for the disease or condition being studied.
In order to participate you must meet the following criteria:
- Are 18 years of age or older.
- Have histologically or cytologically confirmed non-small cell lung cancer.
- Have been deemed medically inoperable.
- Have a body weight >30kg.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.